$AXGN at breakout Pr / financials Nasdaq CM $5.7
Post# of 47
Nasdaq CM $5.75
called 9/15/15 $5.60
Website
First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million
4:57 pm AxoGen reports Q1 in-line, reaffirms 2016 revenue guidance, raises gross margin outlookBriefing.com(Wed 4:57PM EDT)
AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed 4:21PM EDT)
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 MillionGlobeNewswire(Wed 4:10PM EDT)
AXOGEN, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed 4:09PM EDT)
Q1 2016 AxoGen Inc Earnings Release - After Market CloseCCBN(Wed 7:07AM EDT)
Shares Outstanding: 30.04M
Float: 17.38M
% Held by Insiders: 30.89%
% Held by Institutions: 26.90%
Shares Short (as of Apr 15, 2016): 278.70K
Short Ratio (as of Apr 15, 2016): 3.42
Short % of Float (as of Apr 15, 2016): 1.40%
Shares Short (prior month): 278.31K
Headlines
AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It also offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device, as well as provides AxoTouch two point discriminator, a tool used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals through a direct sales force and independent distributors. It markets its products in the United States, the United Kingdom, Israel, Canada, Greece, Chile, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.